Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients by Urbano-Ispizua, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/169956
 
 
 
Please be advised that this information was generated on 2017-12-07 and may be subject to
change.
Different clinical characteristics of paroxysmal 
nocturnal hemoglobinuria in pediatric and adult
patients
Studies of children with paroxysmal nocturnal hemo-
globinuria (PNH) are scarce and include limited numbers
of patients. We compared demographic and clinical char-
acteristics of children and adults in the International PNH
Registry. Our data show that, compared to adults with
PNH, children had smaller PNH clones with more fre-
quent severe cytopenia or previous marrow aplasia. In
contrast, hemolysis was present in similar proportions,
and both children and adults suffered from major adverse
vascular events (MAVE), such as thrombotic events (TE),
which seemed more prominent in adults.
PNH is an acquired clonal hematopoietic stem cell dis-
order characterized by complement-mediated hemolysis,
thrombosis, and bone marrow failure.1-3 It is a very rare
disease with a worldwide incidence estimated at 1.3
cases per million population.4 The onset of PNH is typi-
cally in adulthood, with pediatric cases accounting for
only 5-10% of reported cases;1,5 studies of children with
PNH have, therefore, been limited to case reports and
small series.5-7 The largest PNH pediatric series included
26 patients and was published in 1991, when flow
cytometry was not yet routinely available.1 
The International PNH Registry is the largest PNH data
repository to date, and contains a wide range of laborato-
ry, clinical, and patient-reported information.8 The
Registry is overseen by an independent committee of
international medical PNH experts. Patients with
detectable glycosylphosphatidylinositol (GPI)-deficient
granulocytes or a  “granulocyte PNH clone” (≥0.01%) are
eligible for inclusion in the Registry, regardless of disease
severity, comorbidities, or treatments.  
This retrospective analysis included patients enrolled
in or before June 2015.  Because the objective of this
analysis was to study the natural presentation of PNH,
patients being treated with eculizumab at the time of
enrollment were excluded.  Children were <18 years of
age at the time of disease start and time of enrollment,
while adults were ≥18 years of age at disease start and
enrollment. Patients who were <18 years at disease start
but over 18 years at enrollment were excluded. The
degree of cytopenia was classified using the following cri-
teria:9,10 none (neutrophils ≥1.5x109/L and platelets
≥100x109/L), moderate (neutrophils <1.5x109/L or
platelets <100x109/L), or severe (neutrophils <0.5x109/L
or platelets <20x109/L). Hemolytic activity was defined as
serum lactate dehydrogenase ≥1.5x the upper limit of
normal and/or reticulocytes ≥60x109/L. Duration of dis-
ease was the time between disease start and enrollment
into the Registry. MAVE included TE, as well as pul-
monary embolus, amputation (non-traumatic; non-dia-
betic), myocardial infarction, cerebral arterial occlusion or
transient ischemic attack, unstable angina, and gangrene
(non-traumatic, non-diabetic). Adult and pediatric demo-
graphic and disease characteristics at enrollment were
compared using the Wilcoxon-Mann-Whitney test for
medians and the Pearson c2 test for frequencies. Rates of
TE and MAVE between disease start and enrollment
were calculated per 100 person-years, and 95% confi-
haematologica 2017; 102:e76
LETTERS TO THE EDITOR
Figure 1. Distribution of characteristics in pediatric and adult patients with paroxysmal noctural hemoglobinuria at enrollment. (A) Clone size, (B) cytopenia
status, (C) hemolytic status, and (D) lactate dehydrogenase ratio.
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Table 1. Demographics, medical history, and laboratory characteristics at enrollment in pediatric and adult patients.
Pediatric Adult P
n=99 n=2,268
Age at enrollment, years n=99 n=2,268
Median (min, max) 14.0 (1, 17) 45.0 (18, 99) <0.001
Disease duration at enrollment, years n=99 n=2,268 <0.001
Median (min, max) 0.7 (0, 17) 2.1 (0, 45)
Gender, n (%) n=99 n=2,268
Male 48 (48.5) 1,033 (45.5) 0.566
Female 51 (51.5) 1,235 (54.5)
Race, n (%) n=99 n=2,250
White or Caucasian 87 (88.8) 1,756 (78.0)
Asian 7 (7.1) 399 (17.7) 0.017
Black or African descent 3 (3.1) 44 (2.0)
Other* 1 (1.0)        51 (2.3)             
Unknown 1 0
History of any bone marrow disorder, n (%) n=99 n=2,252 0.004
No 20 (20.2) 766 (34.0)
Yes 79 (79.8) 1,486 (66.0
History of aplastic or hypoplastic anemia, n (%) n=99 n=2,251
No 22 (22.2) 1,027 (45.6) <0.001
Yes 77 (77.8) 1,224 (54.4)
History of myelodysplastic syndrome, n (%) n=99 n=2,250
No 97 (98.0) 2,020 (89.8) 0.007
Yes 2 (2.0) 230 (10.2)
History of TE, n (%) n=99 n=2,260
No 97 (98.0) 2,065 (91.4) 0.020
Yes 2 (2.0) 195 (8.6)
Rate of TE 
Number of TE, n 2 269
Person-years (disease start to enrollment) 162.58 11,880.71 NS
MAVE rate/100 person-years (95% CI) 1.23 (0.15-4.44) 2.26 (2.00-2.55)
History of MAVE, n (%) n=99 n=2,260
No 95 (96.0) 1,934 (85.6) 0.004
Yes 4 (4.0) 326 (14.4)
Rate of MAVE
Number of MAVE, n 4 503
Person-years (disease  start to enrollment) 162.58 11,880.71 NS
Rate/100 person-years (95% CI) 2.46 (0.67-6.30) 4.23 (3.87-4.62)
History of impaired renal function, n (%) n=99 n=2,203
No 93 (93.9) 1,958 (88.9) 0.114
Yes 6 (6.1) 245 (11.1)
History of pulmonary hypertension, n (%) n=99 n=2,249
No 98 (99.0) 2,222 (98.8) 1.000
Yes 1 (1.0) 27 (1.2)
LDH (U/L) n=77 n=1,750
Median (Q1, Q3) 282.0 (213.0, 551.0) 507.5 (274.0, 1247.0) <0.001
LDH ratio n=55 n=1,553
Median (Q1, Q3) 1.3 (0.8, 2.3) 1.6 (0.9,4.2) 0.040
LDH ratio, n (%) n=55 n=1,553
<1.5 33 (60.0) 747 (48.1) 0.083
≥1.5 22 (40.0) 806 (51.9)
Hemoglobin (g/L) n=66 n=2,017 0.990
Median (Q1, Q3) 102.5 (86.0, 120.0) 102.0 (86.0, 122.0)
Absolute reticulocytes (x109/L) n=60 n=1,453 0.072
Median (Q1, Q3) 64.7 (38.1, 120.8) 82.0 (52.6, 134.0)
Percent reticulocytes (%) n=60 n=1,388
Median (Q1, Q3) 2.0 (0.9, 3.6) 2.6 (1.5, 4.5) 0.018
White blood cell count (x109/L) n=87 n=2,051
Median (Q1, Q3) 3.9 (2.7, 4.8) 3.8 (2.8, 5.0) 0.670
LDH: lactate dehydrogenase; MAVE: major adverse vascular event; TE: thrombotic events. 95% CI: 95% confidence interval; Q: quartile. *Includes Native/Aboriginal, Pacific
Islander, unlisted or multiple races. 
dence intervals (95% CI) were based on a Poisson distri-
bution for event counts. 
A total of 2,367 of 3,681 patients enrolled in the
Registry fulfilled the above inclusion criteria for the
analysis: 99 (4.2%) children and 2,268 (95.8%) adults
(Online Supplementary Figure S1). Median (minimum,
maximum) age at enrollment was 14 (1, 17) years for chil-
dren and 45 (18, 99) years for adults; the median duration
of disease at enrollment was shorter in children than in
adults (0.7 years versus 2.1 years, P<0.001) (Table 1).
Children had a shorter average time of observation by
approximately 16.8 months compared to adults. While
most patients in both age groups were White/Caucasian,
there was a lower proportion of patients of Asian ances-
try in the pediatric cohort than among the adults (7.1%
versus 17.7%, P=0.017 for overall comparison of ethnici-
ty). The percentage of GPI-deficient granulocytes differed
between the two cohorts, with more children having
smaller PNH clones at enrollment compared to adults
(<10% clone: 57.3% versus 39.5%, 10-50% clone: 18.0%
versus 21.6%, >50% clone: 24.7% versus 38.9%, respec-
tively; P=0.003 for the overall comparison) (Figure 1A).
More children were classified as having severe cytopenia
at enrollment compared to adults (33.3% versus 13.2%,
P<0.001 for overall comparison) (Figure 1B). Similar pro-
portions were classified as hemolytic at the time of
enrollment (50.0% versus 59.5%, P=0.112) (Figure 1C),
although lactate dehydrogenase levels and reticulocyte
counts were significantly higher in adults (Table 1). A his-
tory of aplastic or hypoplastic anemia at or before enroll-
ment was more frequent in children than in adults
(77.8% versus 54.4%, P<0.001). In contrast, a history of
myelodysplastic syndrome was more frequent among
adults than among children (10.2% versus 2.0%,
P=0.007). A history of TE was less common among chil-
dren than among adults (2.0% versus 8.6%, P=0.020), as
was a history of MAVE (4.0% versus 14.4%, P=0.004).
Using person-years from disease start to enrollment, rates
of TE and MAVE were lower in children than in adults,
although the 95% confidence intervals overlapped due to
low numbers of events: [1.2 (95% CI: 0.2-4.4) and 2.3
(95% CI: 2.0-2.6), respectively, for TE; 2.5 (95% CI: 0.7-
6.3) and 4.2 (95% CI: 3.9-4.6), respectively, for MAVE].
There were no differences in the frequency of impaired
renal function or diagnosed pulmonary hypertension
between the two cohorts. About twice as many children
than adults had received antithymocyte globulin or
immunosuppressive therapy within 12 months of enroll-
ment (59.6% of children versus 28.5% of adults; P<0.001)
(Table 2). The frequency of some symptoms was lower
among children than adults, including dyspnea (20.2%
versus 43.5%, respectively; P<0.001) and hemoglobinuria
(19.3% versus 44.6%, respectively; P<0.001).
This summary of 99 patients with PNH younger than
18 years enrolled in the International PNH Registry rep-
resents more pediatric PNH patients than reported in the
entire published literature to date. The main finding is
that there are substantial differences between the clinical
manifestations and hematologic laboratory values of
these young patients and those of a group of 2,268
patients with PNH older than 18 years. The first observa-
tion was a significant difference in PNH clone size. The
average GPI-deficient clone in children with PNH was
much smaller than in adults, with more than half having
a clone size <10%. A large GPI-deficient clone (>50%) is
typically associated with classical hemolytic PNH, where-
as a small GPI-deficient clone is more frequently
observed in the aplastic anemia-PNH subtype.11 Our lab-
oratory findings support this association: severe cytope-
nia was more frequently observed in children than in
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Table 2. Treatment received by pediatric and adult patients prior to and at enrollment.
Pediatric Adult P
n=99 n=2,268
Any history prior to enrollment
Heparin or warfarin, n (%) n=99 n=2,249
No 91 (91.9) 1,919 (85.3) 0.067
Yes 8 (8.1) 330 (14.7)
ATG or cyclosporine, n (%) n=99 n=2,249
No 37 (37.4) 1,398 (62.2) <0.001
Yes 62 (62.6) 851 (37.8)
RBC transfusion, n (%) n=92 n=1,909
No 26 (28.3) 706 (37.0) 0.090
Yes 66 (71.7) 1,203 (63.0)
Treatment received within 12 months of enrollment
Heparin or warfarin, n (%) n=99 n=2,268
No 93 (93.9) 1,981 (87.3) 0.051
Yes 6 (6.1) 287 (12.7)
ATG or cyclosporine, n (%) n=99 n=2,268
No 40 (40.4) 1,622 (71.5) <0.001
Yes 59 (59.6) 646 (28.5)
RBC transfusion, n (%) n=98 n=2,203
No 43 (43.9) 1,270 (57.6) 0.007
Yes 55 (56.1) 933 (42.4)
ATG: antithymocyte globulin; RBC, red blood cell. 
adults, as was a history of aplastic or hypoplastic anemia,
and twice as many children had previously received
antithymocyte globulin or cyclosporine before or at
enrollment. In a retrospective analysis of 207 patients
with severe aplastic anemia who were treated with horse
antithymocyte globulin from 2000 to 2008, 14 pediatric
patients had a PNH clone >1% at baseline.12 There was a
statistically significant decrease in median clone size in
these patients before and after immunosuppressive ther-
apy over 12 months. Our findings support the concept
that children with hypoplastic or aplastic anemia, even
when successfully treated with immunosuppressive ther-
apy, must be monitored serially for evidence of a GPI-
deficient clone, since late clonal evolution from marrow
failure to PNH can occur.11 Despite having smaller PNH
clones and more often an aplastic component, children
with PNH had evidence of hemolysis at a similar frequen-
cy as adults. We assume, therefore, that many children
with PNH have coexistence of both aplastic and hemolyt-
ic components of PNH. Hemoglobinuria, lactate dehy-
drogenase levels, and reticulocyte counts in children
were significantly lower than in adults, suggesting that
hemolysis was less severe than in adults.   
The size of the GPI-deficient clone has been associated
with the risk of thrombosis. In a large British cohort of
163 unselected PNH patients,13 the incidence of thrombo-
sis was significantly lower among patients with a small
PNH clone, with a 50% threshold suggested for risk of
clinical thrombosis and benefit of primary prophylaxis
with warfarin in this group. Although thrombosis was
less frequent in children, there were several severe cases
and the authors are aware of fatal thrombosis in this set-
ting. It is also well known that severe PNH-related
thrombosis can occur during primary prophylactic antico-
agulation.14 The true incidence of TE in pediatric PNH
has been difficult to determine; previous pediatric series
have reported values as low as 0-4% in Asian cohorts and
as high as 50% among Caucasians.1,5-7,15,16 Our data con-
firm that thrombosis (TE and MAVE) is an important
complication of PNH not only in adults (2.26 per 100 per-
son-years), but also in children (1.23 per 100 person-
years). However, myelodysplastic syndrome or
myelodysplastic features previously reported in two
smaller series5,7 were not confirmed in our registry cohort. 
A limitation of our analyses is the descriptive nature of
the data, which are subject to the inherent limitations of
non-interventional, observational data collection, includ-
ing missing or potentially confounding data. Additionally,
the sample size of the pediatric cohort, as well as the dif-
ferences in time of observation between the pediatric and
adult cohorts precluded further subgroup analyses.
In conclusion, many children with PNH have smaller
GPI-deficient clones than adults, as well as a higher inci-
dence of bone marrow failure, less severe hemolysis, and
probably a lower incidence of thrombosis. Future studies
should examine longitudinal outcomes in pediatric and
adult PNH patients, as well as the impact of conventional
thrombosis prophylaxis and eculizumab or other anti-
complement therapies.  
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